Date and time of publication on KAP: 12.10.2026 11:08:26
https://www.kap.org.tr/en/Bildirim/1679000

KAMUYU AYDINLATMA PLATFORMU

GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş.
Material Event Disclosure (General)

Summary

Signing of Distribution Agreement for New Products

Material Event Disclosure General

Related Companies

Related Funds

Material Event Disclosure General	
Update Notification Flag	Hayır (No)
Correction Notification Flag	Hayır (No)
Date Of The Previous Notification About The Same Subject	-
Postponed Notification Flag	Hayır (No)
Announcement Content	
Explanations	

A Supply and Distribution Agreement has been signed between our Company, GEN İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. and Incyte Biosciences International Sàrl on 9.10.2026.

Within the scope of the said agreement, the exclusive rights for the registration, sales, marketing, and distribution of the following products have been granted to our Company:

- Niktimvo (axatilimab) in Türkiye,
- Opzelura (ruxolitinib) in Türkiye and Azerbaijan.

The term of the agreement has been set at 5 (five) years starting from the date of the first commercial sale of the respective products in the relevant markets.

It is anticipated that this agreement will contribute positively to our Company's commercial activities and growth targets . Material developments regarding the process will continue to be shared with the public and our investors.

Respectfully announced to the public and our investors.

In case of any discrepancy between the Turkish and English texts, the Turkish text shall prevail.

We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.